Comparative Pharmacology
Head-to-head clinical analysis: MOXATAG versus MOXEZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOXATAG versus MOXEZA.
MOXATAG vs MOXEZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin (extended-release) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors, leading to cell lysis and death via activation of autolytic enzymes.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, repair, and recombination.
775 mg orally once daily for 7 days.
400 mg orally once daily with or without food.
None Documented
None Documented
The terminal elimination half-life is 1.0–1.5 hours in healthy adults; however, with the extended-release formulation (Moxatag), the effective half-life is prolonged to support once-daily dosing.
Terminal half-life: 12 hours; allows once-daily dosing
Approximately 60% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 20% is excreted in feces via biliary elimination.
Renal: 70% unchanged; biliary/fecal: 20%; metabolized: 10%
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic